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Abstract
Background: Microalbuminuria (MA) represents the earliest clinical evidence of diabetic
nephropathy and is a predictor of increased cardiovascular morbidity and mortality. The aim of this
study was to determine the prevalence of MA among diabetic patients in the Al-Ain district of the
United Arab Emirates (UAE).
Methods: The study was part of a general cross-sectional survey carried out to assess the
prevalence of diabetes mellitus (DM) complications in Al-Ain district, UAE and was the first to
assess the prevalence of MA among diabetic patients. A sample of 513 diabetic patients with a mean
age of 53 years (SD: ± 13) was randomly selected during 2003/2004. All patients completed an
interviewer-administered questionnaire and underwent medical assessment. First morning urine
collections were obtained and were tested for clinical proteinuria using urine dipsticks and for MA
using the single Micral-Test II strips.
Results: MA was found in 61% (95% CI: 56.7–65.7) of the sample and the rate was significantly
higher among males, positively related to body mass index (BMI), type 2 DM and presence of other
DM complications such as diabetic retinopathy and neuropathy. Of the total sample population,
12.5% (95% CI: 8.1-14.1) had clinical proteinuria.
Conclusion: The prevalence rate of MA  was considerably high ( 61%) among diabetic patients in
the UAE. Therefore, regular screening for MA is recommended for all diabetic patients, as early
treatment is critical for reducing cardiovascular risks and slowing the progression to late stages of
diabetic nephropathy (overt proteinuria and end-stage renal disease).
Background
Diabetes mellitus (DM) has long been recognized as a
major public health problem with far reaching conse-
quences, not only for its adverse health impact on individ-
uals, but also for its economic burden on the health care
system and the society at large [1]. The International Dia-
betes Federation (IDF) in 2005 confirmed that diabetes is
one of the most common non-communicable diseases
globally and constitutes the fourth or fifth leading cause
of death in most developed countries as well as many
developing and newly industrialized countries, such as
the United Arab Emirates (UAE) [2]. The IDF in 2003
ranked the UAE's prevalence rate for type 2 DM and IGT
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for IGT) [2].
Diabetic nephropathy is characterized by proteinuria and
is widely considered as the leading cause of end-stage
renal disease (ESRD) which constitutes the major work-
load of dialysis centers worldwide. Indeed, the costs of
dialysis and renal transplantation imposed by ESRD
implicate a sizeable burden on health care resources [3]
and seriously compromise both the quality of life and life
expectancy [4-7]. It is well known that progression to
established diabetic nephropathy occurs through several
stages. MA, defined as urinary albumin excretion rate of
20–200 ug/min on a timed specimen without an alterna-
tive clinical explanation (such as urinary tract infection,
heart failure or exercise in the past 48 hours) or urinary
protein excretion rate of 30–300 ug/min, is a known pre-
dictor of future developments of overt diabetic nephropa-
thy [8]. Because MA can be reversed and the future
developments of overt diabetic nephropathy can be signif-
icantly reduced, screening for MA and the timely thera-
peutic intervention has become the standards of care
worldwide.
Screening for MA can be performed using quantitative
methods, including: i) measurement of albumin to creat-
inine ratios in a random urine sample; ii) a 24-hour col-
lection with creatinine, allowing the simultaneous
measurement of creatinine clearance; iii) timed (e.g. 4
hour) overnight urine collection for protein, or by using
semi-quantitative reagent dipsticks specifically designed
with detection limits suitable for identifying microalbu-
minuria, such as the Micral dipsticks [9].
According to the American Diabetes Association (ADA),
when using the random collection technique, normal
albumin excretion should be defined as <30 mcg/mg of
creatinine; microalbuminuria 30 to 299 mcg/mg of creat-
inine, and macroalbuminuria is 300> mcg/mg of creati-
nine [10]. In the 24-hour collection technique, albumin
excretion <30 mg per 24 hours is considered normal, 30
to 299 mg per 24 hours indicates microalbuminuria, and
300 mg or higher indicates macroalbuminuria [10]. When
using the timed collection technique, normal albumin
excretion is defined as <20 mcg/min, microalbuminuria is
defined as 20 to 199 mcg/min, and macroalbuminuria as
200> mcg/min [10].
Screening for MA with Micral-test II strips is relatively
cheap, fast and has an acceptable sensitivity of 97% with
a specificity of 71% [9]. Several studies comparing Micral
test II and laboratory methods of detecting albuminuria
have concluded that the test could be used as a screening
tool but, because of its low specificity, cannot be used as a
diagnostic tool [11-13]. Micral test II is an optically read
immunoassay, specifically designed for detection of MA
and the use of these strips has been widely advocated [9].
Generally, screening for MA is relatively cheap and con-
venient procedure to detect MA among diabetic patients
to reduce cardiovascular risks and the rate of progression
of diabetes-related nephropathy. To our best knowledge
our study constitutes the first effort in the UAE to estimate




The study was part of a general cross-sectional survey of
DM patients carried out to assess and establish the preva-
lence of DM complications including MA among diabetic
patients in Al-Ain District, UAE, using the single Micral-
Test II strips.
Subjects and setting
The sampling frame of this study included all nationals
and non-nationals diabetic patients of all ages and both
genders attending any primary health care center (PHCC)
for any reason and diabetic clinics at hospitals for follow
up in Al-Ain district of Abu Dhabi. Power and sample esti-
mations were used to estimate a sample size with a stand-
ard error of 2%. Accordingly, a sample size of 625 patients
was estimated. To achieve that all PHCC and diabetic clin-
ics in the district were enlisted and enumerated and multi-
stage random sampling was used to select 8 PHCC (a
proportion of 25% out of 22 rural and urban PHCC) in
addition to two diabetic clinics at the two main public
hospitals in Al-Ain district. In the absence of a diabetes
registry or a computerized database for patients in the dis-
trict, systematic random sampling was used to select
patients to be approached for participation in the study.
Therefore, every third DM patient visiting the participant
PHCC and diabetic clinics was approached. In total, 600
patients were approached by general practitioners and
diabetologists, out of which 513 patients (86%) agreed to
enroll. The study was approved by the Joint Ethics Com-
mittee of the Faculty of Medicine and Health Sciences of
the UAE University and the Al-Ain Medical District. The
data were collected between September 2003 and May
2004.
Data collection
After receiving a prior informed consent (a written one
from literate patients and a verbally informed one from
illiterate patients), participant patients were interviewed
by their treating doctors about DM type, duration, treat-
ment profile, level of control, presence or absence of
chronic DM complications. The diagnosis of diabetes was
based on self reported physician diagnosis of diabetes.
Participants who were not responding to oral hypoglyc-Page 2 of 8
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years of diagnosis were classified as having type 1 diabe-
tes. All other cases were classified as type 2 diabetes.
Blood pressure (BP) was measured early in the morning
and prior to drawing of blood samples using a suitable
mercury sphygmomanometer after a 10 minutes rest with
the patient in the sitting position. BP was measured two
times at 5 minutes interval. The first and the fifth koro-
tokoffs sound were used to determine the systolic and
diastolic blood pressure measurement, respectively. The
second blood pressure measurement was used as the
blood pressure for the individual. The WHO definition of
hypertension was used in this study: systolic blood pres-
sure 160 mmHg or more and/or a diastolic blood pressure
95 mmHg or more [14], or if the patient is on treatment
with antihypertensive drugs. Height was measured with-
out shoes, and weight was recorded while wearing indoor
clothing. Body mass index (BMI) (weight in Kg, divided
by height in meters squared) was calculated. The WHO
(1995, 2002) classification for BMI was used to estimate
the degree of obesity [15]. A standard 12-lead electrocar-
diogram (ECG) was recorded for all patients. Fasting
blood samples were taken to assess lipid profile, blood
sugar and glycated hemoglobin (HbA1C) levels. Total lipid
profile (total cholesterol (TC), high density lipoprotein
(HDL), TC/HDL ratio, low density lipoprotein (LDL) and
triglycerides) was measured by a capillary tube whole
blood method using the Cholesterol LDX lipid analyzer.
Dyslipidaemia was taken to be present when the total cho-
lesterol was >5.60 mmol/L and/or triglycerides >2.10
mmol/L, LDL >3.4 mmol/L, and/or HDL <0.91 mmol/L.
Fasting blood glucose was measured by glucose oxidase
method; Clinical Chemistry Analyzer. Glycated haemo-
globin (HbA1C) was measured using the Bayer DCA
2000+ analyzer and a value of less than 7% was taken to
indicate good glycemic control.
The diagnosis of diabetic nephropathy was made when
MA and/or clinical proteinuria was detected and other
causes of kidney disease or alternative explanations for
proteinuria such as urinary tract infection (UTI), marked
hypertension, heart failure and febrile illness were
excluded. Patients who had undergone renal transplanta-
tion or were treated with dialysis with no other reason for
renal failure were also considered to have diabetic neph-
ropathy. Proteinuria was defined by the presence of pro-
tein in the urine using the conventional test strips (Redia,
Boehringer-Mannheim, Mannheim, Germany). Two cate-
gories of proteinuria were identified: severe level; in those
with heavy proteinuria (≥3+); and trace or intermediate
level in those who had (<3+) urinary protein. Urinary
albumin concentration was measured by using semi-
quantitative dry immuno chemical screening strips
(Micral II ® test strips (Roche diagnostic GmbH Man-
nheim Germany). Micral Tests were performed on first
morning urine collections and a value of more than 20
µg/min was judged as pathological. Chronic renal failure
was defined by a serum creatinine level > 3 mg/dL [16].
Cardiovascular complications were ascertained using
standard procedures. Coronary artery disease was identi-
fied by symptoms of definite angina pectoris or of definite
past myocardial infarction and/or ECG changes consistent
with previous myocardial infarction. Peripheral neuropa-
thy was determined by Diabetic Neuropathy Symptoms
(DNS) [17] and the Diabetic Neuropathy Examination
(DNE) scores [18]. Neuropathy was considered to be
present if DNS score was > 0 and/or the DNE score was >3.
The presence of retinopathy was confirmed by fundus
photography using digital camera.
Statistical analysis
The data was coded and processed on IBM compatible
computers, using the Statistical Package for Social Sci-
ences (SPSS) software (version 14). Descriptive analysis,
using standard statistical methods was performed. Chi-
square tests or Fisher's exact test, independent t-tests and
Pearson correlation coefficient were used to ascertain the
association between MA and clinical outcome variables.
A multiple logistic regression model with backward selec-
tion (criterion: probability of F to remove ≥ 0.10) was
used to estimate the effect of microalbuminuria (MA)
among the sample population. The method enters all
independent variables in the equation and then sequen-
tially removes them. The variable with the smallest partial
correlation with the dependent variable (Yi) is considered
first for removal. If it meets the criterion for elimination,
it is removed. After the first variable is removed, the vari-
able with the smallest partial correlation remaining in the
equation is considered next. The procedure stops when
there are no variables in the equation that satisfy the
removal criterion.
The variables included as predictors were: sex, type of DM,
age group, duration of disease (in years), nationality and
BMI group. That is in addition to a number of determi-
nants of dichotomous (yes/no) outcomes related to DM
including presence of coronary artery disease, diabetic
retinopathy and neuropathy. Missing values for variables
were replaced with the variable mean. ANOVA was used
to estimate overall and individual significance of regres-
sion parameters. For overall significance the test statistic F
was used to test parameters Bij for significance. For indi-
vidual parameters the t-test was used. According to princi-
ples, the overall significance of the model was used as
evidence for the suitability of the model.Page 3 of 8
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Socio-demographic characteristics of the study population
A total sample (n = 600) of male and female diabetic
patients of all nationalities (UAE nationals and expatri-
ates) resident in the Al-Ain district of Abu Dhabi emirate
was selected; of whom, 513 agreed to enroll. Of the total
sample, 52% were males, 27% aged 60 or above, 75%
were UAE nationals and most patients (63%) were illiter-
ate. Of the total sample 13% (95% CI: 11.0–14.6) were
currently smoking while 8.2% (95%CI: 6.7–9.7) were ex-
smokers and 76% were obese or overweight (Table 1).
Clinical characteristics
The majority of the sample population (86%) had Type 2
DM; 49% were diagnosed incidentally and most of them
(79%) had been diabetic for ≥10 years. Of the total popu-
lation, 35% (95%CI: 30.8–39) had hypertension. The
majority of patients (84%) were partially managed by oral
hypoglycemic agents, 24% by insulin while two thirds
were not following any exercise regime as part of their DM
management. The analysis of glycemic control of patients
using HbA1C showed that 38% (95%CI: 32.8–42.4)) had
good glycemic control (Table 2). Dyslipidaemia, assessed
by elevated total cholesterol, was present in 34% (95%CI:
30.0–38.8) and elevated triglycerides was present in 24%
(95% CI: 19.9-27.9) of the sample population.
Prevalence of nephropathy
Of the total sample, MA was assessed in 451 patients. The
most common reason for missing cases was patients' fail-
ure to bring first void urine samples. The analysis of the
sample population showed that 12.5% (95% CI: 8.1–
14.1) had clinical proteinuria; 11.1% had trace, 1+ and 2+
and only 1.4% had gross proteinuria (3+ or greater).
Chronic renal failure was found in 3 patients only. MA
was present in 61.2% (95% CI: 56.7–65.7) of the sample
population. The univariate analysis showed that MA was
slightly more frequent in males (53.3% vs 46.7%) com-
pared to females and was significantly higher among over-
weight and obese compared to the normal weight
individuals (80% vs 18.8%) (p = 0.002). The presence of
MA was statistically significantly associated with presence
of chronic complications of DM such as coronary artery
disease (p = 0.03), diabetic retinopathy (p = 0.07) and
diabetic neuropathy (p = 0.01). MA was also more com-
mon among patients with type 2 DM compared to those
Table 1: Baseline Characteristics of DM Patients in Al-Ain 
District, UAE, 2003–2004 (n = 513)
Variable name Prevalence of DM
n Percent (95% CI)
Sex
Male 264 51.5 (47.2–55.8)
Female 249 48.5 (44.2–52.8)
Level of Education
Illiterate 318 62.8 (58.6–67.0)
Completed primary school 99 19.6 (16.1–23.1)
Completed secondary school 60 11.9 (9.1–14.7)
Completed university 29 5.7 (3.7–7.7)
Age group (Years)
40 or less 81 15.8 (12.6–19.0)
41 – 49 137 26.8 (23–30.6)
50 – 59 154 30.1 (26.1–34.1)
60 or above 140 27.3 (23.4–31.2)
Nationality group
UAE 382 74.6 (70.8–78.4)
Other Gulf countries citizens 54 10.5 (7.8–13.2)
Arabs from other countries 54 10.5 (7.8–13.2)
Asians 22 4.3 (2.5–6.1)
Smoking
Current smoker 64 12.8 (11.0–14.6)
Ex smoker 41 8.2 (6.7–9.7)
BMI Group
Under weight (<18.5) 6 1.2 (0.2–2.2)
Healthy weight (18.5–24.99) 113 22.5 (18.8–26.2)
Overweight (25–29.99) 195 38.8 (34.5–43.1)
Obese (>30) 188 37.7(33.3–41.7)
Table 2: Clinical Characteristics of DM Patients in Al Ain 
District, UAE, 2003–2004 (n = 513)
n Percent (95% CI)
Type of DM
Type 1 68 13.6 (10.6–16.6)
Type 2 431 86.4 (83.4–89.4)
Mode of Diagnosis
Incidental 245 48.5 (44.1–52.9)
Screening 39 7.7 (5.4–10.0)
Symptomatic 221 43.8 (39.5–48.1)
Family History of DM
Present 270 54.3 (49.9–58.7)
Duration of the Disease
< 1 year 33 6.6 (4.4–8.8)
1–5 years 199 40.0 (35.7–44.3)
6–10 years 161 32.3 (28.2–36.4)
11–20 years 98 19.7 (16.2–23.4)
>21 years 7 1.4 (0.4–2.4)
Hypertension
Present 178 34.9 (30.0–38.8)
Total Cholesterol
High (>5.60 mmol/L) 152 34.4 (30.0–38.8)
Triglycerides
High (>2.10 mmol/L) 105 23.9 (19.9–27.9)
HDL
Low (<0.91 mmol/L) 36 25.7 (18.5–32.9)
LDL
High (>3.4 mmol/L) 70 53.4(44.9–61.9)
Microalbuminuria
Present (>20 µg/min) 276 61.2 (56.7–65.7)
HBA1c
Good control (<7%) 150 37.6(32.8–42.4)
Poor control (>7%) 246 62.4(57.6–67.2)Page 4 of 8
(page number not for citation purposes)
BMC Nephrology 2008, 9:1 http://www.biomedcentral.com/1471-2369/9/1with type 1, and the results were statistically significant (p
< 0.04) (Table 3). The prevalence of MA showed no statis-
tically significant associations with other covariates,
including patient's age, nationality, disease duration, and
presence of hypertension, dyslipidaemia or glycemic con-
trol.
A backward stepwise multiple logistic regression analysis
with backward selection of factors that might independ-
ently be associated with development of microalbuminu-
ria was performed on a number of predictors including,
type of DM, age group, sex, DM duration (in years),
nationality, BMI group, presence of coronary artery dis-
ease, diabetic retinopathy and diabetic neuropathy. The
results demonstrated a statistically significant association
between MA and the following covariates: male sex
(adjusted OR: 0.48; 95% CI: 0.267–0.893), type 2 DM
(adjusted OR: 4.309; 95% CI: 1.590–11.673), high BMI
(adjusted OR: 0.614; 95% CI: 0.421–0.897), UAE nation-
ality (adjusted OR: 0.706; 95% CI: 0.512–0.972), pres-
ence of diabetic neuropathy (adjusted OR: 5.811; 95% CI:
3.040–11.106) and retinopathy (adjusted OR: 2.800;
95% CI: 1.303–6.017) (Table 4). Patient age, disease
duration, and presence of coronary artery disease were not
significantly associated with MA and as such were
removed by the model from the equation.
Table 3: MA in Relation to Baseline Characteristics of the Study Population, in Al Ain District, UAE, 2003–2004 (n = 513)
Variable name MA Present MA Absent
n Percent n Percent p-value
Sex
Female 129 46.7 96 54.9 0.09
Male 147 53.3 79 45.1
Type of DM
Type 1 42 15.8 16 9.2 0.04
Type 2 224 84.2 157 90.8
BMI
Under weight (<18.5) 1 0.4 4 2.4 0.002
Healthy weight (18.5–24.99) 51 18.8 43 25.4
Overweight (25–29.99) 98 36.2 75 44.4
Obese (>30) 121 44.6 47 27.8
Nationality
UAE nationals 209 75.7(70.6–80.8) 132 75.9(69.5–82.3) 0.09
Gulf countries citizens 25 9.1(5.7–12.5) 23 13.2(8.2–18.2)
Arabs from other countries 34 12.3(8.4–16.2) 11 6.3(2.7–9.9)
Asians 8 2.9(0.9–4.9) 8 4.6(1.5–7.7)
Coronary Artery Disease
Present 31 11.4 32 18.4 0.03
Absent 242 88.6 142 81.6
Neuropathy
Present 118 42.9 52 31 0.01
Absent 157 57.1 116 96
Retinopathy
Present 28 15.2 27 23.5 0.07
Absent 156 84.8 88 76.5
Table 4: Multivariate Analysis of Predictors for MA among DM Patients in Al-Ain District, UAE, 2003–2004 using stepwise Logistic 
Regression
Variable Regression coefficient P value Adjusted OR 95% CI
Male gender -0.717 0.02 0.488 0.267–0.893
Type 2 DM 1.461 0.004 4.309 1.590–11.673
UAE Nationality -0.348 0.033 0.706 0.512–0.972
High BMI -0.487 0.012 0.614 0.421–0.897
Presence of DR 1.030 0.008 2.800 1.303–6.017
Presence of DN 1.760 0.000 5.811 3.040–11.106
DR-Diabetic Retinopathy. DN-Diabetic NeuropathyPage 5 of 8
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Diabetic nephropathy defined clinically as the presence of
MA or overt nephropathy in patients with diabetes who
lack indicators of other renal disease, is the most common
cause of renal failure in the industrialized countries [4]
and is now considered the commonest cause of ESRD
worldwide. It is also widely acknowledged as an inde-
pendent risk factor for cardiovascular disease [5]. MA is
the first clinically detectable stage of involvement of the
kidney, and affects between 20–40% of diabetic patients.
Several epidemiological studies reported prevalence rates
of MA ranging between 8–32% among type 2 diabetic
Asian patients [19,20]. The variation in prevalence rates is
most probably attributable to differences in diagnostic cri-
teria, the stage of the disease, the method of assessment
and ethnicity [21].
This study is the first cross sectional analysis assessing the
prevalence of MA among diabetic patients in the UAE. The
analysis showed an overall prevalence rate of MA amount-
ing to 61% among the sample patients. This rate was
clearly higher than the equivalent rates reported in the
Arabian Gulf countries [22-24] and the differences could
be attributed to the method of assessment or study design.
It is established that once MA is present, it is most likely
to progress to proteinuria, over the next 5–10 years, in 20–
50% of subjects. With the presence of MA, it is known that
the decline in renal function varies but the average loss in
glomerular filtration remains around 10–12 ml/min/year
[25], and is accelerated by hypertension [26], though it is
potentially reversible [27]. MA is also strongly associated
with traditional cardiovascular risk factors and cardiovas-
cular complications and events. Mogensen et al (1984)
reported a significant increase in cardiovascular and total
mortality in subjects with type 2 diabetes who had MA
[28]. Dineen and Gerstein drew similar conclusions from
a meta-analysis of 11 longitudinal studies [29]. MA is also
associated with other diabetes complications such as
retinopathy and neuropathy [30-33]. The association is
held even after adjustment for other cardiovascular risk
factors such as age, hypertension, smoking, dyslipidemia,
abdominal obesity and hyperglycemia [34].
Similar to studies elsewhere, this study confirm that MA is
statistically significantly associated with some adverse car-
diovascular risk profile [35-38]. The univariate analysis
showed that MA is significantly associated with the pres-
ence of coronary artery disease, diabetic retinopathy and
neuropathy; though the latter was of borderline signifi-
cance (p = 0.07). However, the multivariate logistic regres-
sion analysis demonstrated strong associations between
MA and DM retinopathy (adjusted OR: 2.800; 95% CI:
1.303–6.017) and MA and DM neuropathy (adjusted OR:
5.811; 95% CI: 3.040–11.106).
Several risk factors have been identified for the presence of
MA after adjustment for age and sex. Of significant impor-
tance were type 2 DM, UAE nationality, male sex, and
obesity. As pointed out earlier, the results of many studies
in other populations have shown that type 2 DM is com-
monly associated with higher prevalence of nephropathy
[28]. Similarly, obesity, specifically with central fat distri-
bution, is commonly known to be associated with urinary
albumin excretion independent of blood pressure and
plasma glucose [39-42].
Many studies have shown statistically significant associa-
tions between MA and insulin resistance [43] and the
WHO definition of metabolic syndrome lists MA as one of
the important components of the syndrome. Generally,
our results were consistent with the findings of those stud-
ies [44,45]. However, our data showed no significant
association between presence of MA and some known risk
factors such as hypertension, degree of glycemic control,
age and duration of diabetes. This could be attributed to
the fact that our study was cross-sectional and as such its
results cannot be used to correctly trace or establish the
role for any of these factors in the development of MA in
the sample patients.
The study has few limitations. Firstly, sampling from clin-
ics may not be representative to all patients and/or the
general population as undiagnosed subjects may be
excluded. Secondly, the design was cross-sectional and
therefore, causal relationships cannot be ascertained.
Thirdly, it is known that DM is notoriously under-diag-
nosed, and therefore, the results shown might reflect only
the tip of the iceberg. Fourthly, the proxy definition of DM
was used in the study and auto antibodies screening such
as Anti-GAD analyses was not assessed for all patients. As
such it is likely that some type 2 diabetes are misclassified
as type 1. Finally, the data from patients in Al-Ain may not
represent all patients living in other parts of the UAE
regions.
Conclusion
In conclusion, the fact that MA could lead to adverse out-
comes in patients, and the recognition that the risk factors
for MA and its clinical course are amenable to interven-
tion, provide a genuine case for action. MA is often incip-
ient and can only be detected by special tests, such as the
annual screening for MA, recommended by the American
Diabetes Association, which is highly cost-effective. The
availability of highly sensitive, cheap, dip-stick technol-
ogy, strengthens the case for regular screening. Early detec-
tion of diabetic nephropathy, adoption of multifactorial
interventions targeting its main risk factors and the use of
renal-protective agents such as ACE inhibitors might
reduce the progression of renal disease. Treatment of
hypertension is a priority and the early attention to thesePage 6 of 8
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